ALKEM

Feb 16 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABS - USFDA ISSUES FORM 483 WITH 6 PROCEDURAL OBSERVATIONS

• ALKEM LABS - USFDA INSPECTION AT MANUFACTURING FACILITY OF ENZENE BIOSCIENCES

Source text: ID:nBSE6BrxyZ

Further company coverage: ALKE.NS

(([email protected];;))

BENGALURU, Feb 13 (Reuters) - Alkem Laboratories' ALKE.NS medical devices unit will buy a stake of up to 55% in Switzerland-based Occlutech Holding for 99.4 million euros ($117.9 million), the pharmaceutical company said on Friday.

($1 = 0.8430 euros)

(Reporting by Nishit Navin; Editing by Sonia Cheema)

(([email protected];))

Rewrites to add new information throughout

By Rishika Sadam and Kashish Tandon

Jan 23 (Reuters) - Indian drugmakers Sun Pharmaceutical Industries SUN.NS, Zydus Lifesciences ZYDU.NS and Alkem Laboratories ALKE.NS have received approval from India's regulator to manufacture and sell generic versions of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic.

Data on the regulator's website show Zydus Lifesciences ZYDU.NS and Alkem Laboratories ALKE.NS received approval last week to manufacture and sell generic semaglutide for weight-loss and diabetes treatment, intensifying competition in the obesity-drug race in the world's most populous nation.

The companies, which are yet to announce the approval, did not immediately respond to Reuters' request for a comment.

Sun Pharma, which is India's largest drugmaker by revenue, on Friday announced that it had been granted approval and would be launching generics under brand names Noveltreat for obesity and Sematrinity for diabetes.

Semaglutide, the active ingredient in Danish drugmaker Novo Nordisk's NOVOb.CO Wegovy and its diabetes drug Ozempic, is set for patent expiry in March 2026.

The upcoming patent expiry for semaglutide opens the door for Indian generic drugmakers to enter the weight-loss market with cheaper versions of both Wegovy and Ozempic at steep discounts.

Last year, U.S. drugmaker Eli Lilly LLY.N launched Mounjaro in India, while Novo introduced Wegovy and Ozempic. Sales of the innovator drugs doubled shortly after launch.

The global weight-loss drug market is projected to reach $150 billion by the end of the decade.

Ozempic, though mainly approved for type 2 diabetes, is also used off-label for weight loss due to its appetite-suppressing effects.

Earlier this week, Dr Reddy's Laboratories REDY.NS said it had obtained approval to sell the generic version of Ozempic.

"The generic players will come in with lower prices and expand the number of people they can reach out to given their aggressive marketing strategy," said Vishal Manchanda, an analyst with Systematix Institutional Equities, adding that there are at least a dozen other generic companies awaiting approvals.

(Reporting by Rishika Sadam in Hyderabad and Kashish Tandon in Bengaluru; Editing by Sherry Jacob-Phillips and Tasim Zahid)

(([email protected]))

Jan 13 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABS - GETS TAX DEMAND OF 38.3 MILLION RUPEES; TAX PENALTY OF 3.8 MILLION RUPEES

Source text: ID:nnAZN4RXVG9

Further company coverage: ALKE.NS

(([email protected];))

Jan 8 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• LAUNCHES RENOCIA CYCLICAL THERAPY KIT TO SUPPORT HAIR GROWTH

Source text: ID:nNSE6cDgf2

Further company coverage: ALKE.NS

(([email protected];))

Jan 1 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• GETS TAX PENALTY OF 10.9 MILLION RUPEES

Source text: ID:nNSE9Lr9b5

Further company coverage: ALKE.NS

(([email protected];))

Nov 13 (Reuters) - Alkem Laboratories ALKE.NS:

• SEPT-QUARTER CONSOL NET PROFIT 7.65 BILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 40.01 BILLION RUPEES

Source text: ID:nBSEBpBhz

Further company coverage: ALKE.NS

(([email protected];))

Sept 24 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• GETS TAX ORDER DEMAND OF 2.3 MILLION RUPEES

Further company coverage: ALKE.NS

(([email protected];;))

** Alkem Laboratories ALKE.NS rises 0.5% to 5,451 rupees

** Nomura retains "buy"; raises PT to 6,300 from 5,393 rupees, implying 16.2% upside to last close

** Sees recovery in domestic business, growth potential in Enzene Biosciences, Alkem's biotechnology subsidiary

** Sees growth opportunity in co's obesity drug

** Expects Enzene revenue to rise to 8 bln rupees ($91.5 mln) by FY28 vs year-ago 3.6 bln rupees

** Stock rated "hold" on avg; median PT is 5,430 rupees, per data compiled by LSEG

** YTD, ALKE falls 3.2%

($1 = 87.4300 Indian rupees)

(Reporting by Rudra Singh)

(([email protected];))

** Alkem Laboratories ALKE.NS rises 4.5% to 5,064 rupees; marks biggest intraday pct gain since May 6

** Pharma products maker posts ~22% y/y rise in June-quarter consol net profit; consol rev from ops up 11.2% y/y

** More than 131,357 shares traded, 1.2x the 30-day avg

** Stock rated "hold" on avg; median PT is 5,022.5 rupees, per data compiled by LSEG

** YTD, ALKE down 10%

(Reporting by Rudra Pratap Singh in Bengaluru)

(([email protected]))

BENGALURU, May 29 (Reuters) - Diary of India economic, corporate events on May 29

ECONOMIC, CORPORATE .BSE500 EVENTS:

NTS - 'No time scheduled'

(Compiled by Bengaluru Newsroom)

(([email protected]))

April 23 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABORATORIES LTD - ACQUIRES 100% STAKE IN ADROIT BIOMED

Source text: ID:nBSE2FvKDC

Further company coverage: ALKE.NS

(([email protected];;))

Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABORATORIES LTD - RECEIVES GST DEMAND ORDER FOR 13.7 MILLION RUPEES

Source text: ID:nBSE2Pb2ks

Further company coverage: ALKE.NS

** Shares of Alkem Labs ALKE.NS down 6.4% to 5,151 rupees

** Stock top percentage loser on the Nifty Pharma index .NIPHARM, which is down 1.8%

** The pharma co posted a 5.2% YoY increase in quarterly net profit and a 1.5% rise in revenue on Friday, but both fell short of analysts' estimates

** Brokerage J.P. Morgan cuts its FY25/26/27 earnings estimates by 4%/3%/8% due to softer revenue trends

** Co maintained FY25 EBITDA margin target at 19%, indicating a weak Q4 ahead - J.P. Morgan

** Brokerage adds, concerns remain due to weak India growth and lackluster U.S. portfolio

** Stock rose 8.3% in 2024 vs a 39% gain in .NIPHARM

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Feb 7 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM MEDTECH TO ACQUIRE 100% STAKE IN BOMBAY ORTHO INDUSTRIES

Source text: ID:nBSEhXggz

Further company coverage: ALKE.NS

(([email protected];;))

Feb 4 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABS - LAUNCHES KOJIGLO SERUM IN INDIA TO MANAGE FACIAL HYPERPIGMENTATION

Source text: ID:nBSE6t76MZ

Further company coverage: ALKE.NS

(([email protected];;))

Jan 7 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABORATORIES LTD - GETS GST ORDER OF 52.2 MILLION RUPEES, PENALTY OF 52.2 MILLION RUPEES

Source text: [ID:]

Further company coverage: ALKE.NS

(([email protected];))

Dec 25 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• IT AUTHORITY DISALLOWS TAX DEDUCTION

• DISPUTED AMOUNT IS 3.75 BILLION RUPEES

• NO MATERIAL IMPACT ON COMPANY AS NO AMOUNT IS PAYABLE

Source text: ID:nBSE8Pxk02

Further company coverage: ALKE.NS

(([email protected];))

** Shares of Alkem Labs ALKE.NS rise 2.4% to 5,526 rupees

** Stock among top gainers on the Nifty Pharma index .NIPHARM, which is up 1.44%

** The pharma co said on Tuesday it entered into an agreement for equity investment in Sunsure Solarpark by investing 19.5 mln rupees ($229,633)

** Sunsure Solarpark engaged in business of generation, production and distribution of electricity from renewable energy sources

** Eighteen analysts covering the stock on avg have a "hold" rating; median PT is 6,053 rupees - LSEG data

** Stock up 6% YTD vs a 33% gain in .NIPHARM

($1 = 84.9180 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected]))

Dec 17 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABS - ENTERED AGREEMENT FOR EQUITY INVESTMENT IN SUNSURE SOLARPARK

• ALKEM LABS - INVESTMENT OF 19.5 MILLION RUPEES

Source text: [ID:]

Further company coverage: ALKE.NS

(([email protected];))

Dec 10 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• APPROVES TRANSFER OF TRADE GENERICS BUSINESS TO ALKEM WELLNESS

• CONSIDERATION EXPECTED TO BE UP TO 7.50 BILLION RUPEES

Source text: ID:nBSE1ZqG4j

Further company coverage: ALKE.NS

(([email protected];))

Nov 13 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• SEPT-QUARTER CONSOL NET PROFIT 6.89 BILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 34.15 BILLION RUPEES

Source text: ID:nBSE1s1WRP

Further company coverage: ALKE.NS

(([email protected];))

By Bharath Rajeswaran

Nov 7 (Reuters) - MSCI added five Indian companies to its Global Standard Index late on Wednesday, a move that brokerage Nuvama said would lift the country's weightage on the index to 20%, further narrowing the gap with China.

MSCI said there would be 156 Indian stocks in the index, but that is only one-fourth of China's 598, signalling scope for further inclusion of Indian stocks on the index.

The changes will take place after the markets close on Nov. 25, MSCI said.

The inclusion of the stocks will lift India's weightage in the index to a record 19.8% from 19.3% earlier, narrowing the gap with China, which has slipped to 26.8% from 27%, Nuvama Alternative and Quantitative Research estimated.

It will also likely attract $2.5 billion in passive inflows into India's equity markets, Nuvama said.

China has the highest weightage in the MSCI Global Standard index, while India has been in second place since the end of 2021.

Air conditioner maker Voltas VOLT.NS, realty developer Oberoi Realty OEBO.NS, stock exchange operator BSE BSEL.NS, Kalyan Jewellers KALN.NS, and drug maker Alkem Laboratories ALKE.NS are the latest additions to the index.

Indian markets saw inflows of about $3 billion into equities after the previous MSCI rebalancing in August when seven stocks were added.

"We remain extremely bullish on India, especially with active participation from mutual funds and high net worth individuals (HNIs)/retail investors, and anticipate many more inclusions in the emerging markets index," said Abhilash Pagaria, head of Nuvama research.

Seven existing stocks, including top private lender HDFC Bank HDBK.NS and Tata Power TTPW.NS, saw an increase in their weightage.

HDFC Bank is now the highest-weighted Indian stock in the MSCI indices at 7.08%, surpassing Reliance Industries' RELI.NS 6.08%.

No Indian companies have been removed from the MSCI Global Standard Index so far in November.

Additionally, around 13 firms, including Eureka Forbes EURK.NS, Indegene INEG.NS, and PC Jeweller PCJE.NS, were added to the MSCI Small Cap Index, bringing the total number of small-cap stocks to 525.

(Reporting by Bharath Rajeswaran in Bengaluru; Editing by Abinaya Vijayaraghavan)

(([email protected]; +91 9769003463;))

Oct 10 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• SIGNED A LICENSING AGREEMENT WITH SONNET BIOTHERAPEUTICS HOLDINGS

• SIGNS LICENSING AGREEMENT WITH SONNET BIOTHERAPEUTICS HOLDINGS, INC

• TO DEVELOP, COMMERCIALIZE 'SON-080' FOR TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY

• ALKEM HAS EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE AND COMMERCIALISE DRUG IN INDIA

• CO TO CARRY OUT CLINICAL DEVELOPMENT OF "SON-080" IN INDIA TO ENABLE REGULATORY FILINGS

Source text for Eikon: ID:nBSE9MwnfJ

Further company coverage: ALKE.NS

(([email protected];))

Sept 27 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABS - DENIES CLAIMS OF PAN-D, CLAVAM 625 BATCHES BEING NOT-OF-STANDARD QUALITY

• ALKEM LABS - ALL PRODUCTS MANUFACTURED AT OUR SITES FOLLOW CURRENT GOOD MANUFACTURING PRACTICES

• ALKEM LABS - SAMPLES OF PRODUCTS MENTIONED IN CDSCO LIST ARE SPURIOUS, NOT MANUFACTURED BY ALKEM

Source text for Eikon: ID:nBSE7nqD6X

Further company coverage: ALKE.NS

(([email protected];;))

By Rishika Sadam

BENGALURU, Sept 26 (Reuters) - India's drug regulator has found more than 50 drugs, including some batches of widely used antacids and paracetamol, to be substandard or fake, according to government documents.

The regulator, Central Drugs Standard Control Organisation, releases a monthly list of substandard or fake medicines sold in the country after routine tests across the country by multiple agencies.

The regulator found some drugs as "not of standard quality", including a batch each of Alkem Laboratories' ALKE.NS popular antacid Pan-D, Hetero's anti-infective Cepodem and Shelcal, a vitamin and calcium tablet brand made by privately-owned Pure & Cure Healthcare, and several antibiotics, according to the lists for August.

Sun Pharmaceutical Industries SUN.NS separately informed the regulator of a fake batch of Pantocid, a popular Indian brand of an antacid called pantoprazole. The agency said it is investigating the matter.

Fake, or "spurious", batches of Sun's drug Pulmosil, used to treat high blood pressure in the lungs, and Glenmark Pharmaceuticals' GLEN.NS anti-hypertension drug Telma H, among others, were also notified by the companies to the regulator and were being investigated.

"When a medicine is found to be below quality standards, the drug regulator sends a notice to the manufacturer to check and recall that batch of product. Companies too conduct their own tests on leftover samples to check for the possibility of counterfeit," said Rajiv Singhal, general secretary of drug retailer body All India Organisation of Chemists and Druggists.

The companies did not immediately respond to Reuters' request for comment.

Gastrointestinal, anti-diabetic, vitamins and nutraceutical drug sales were one of the top contributors to the domestic pharma market growth in August, according to research firm Pharmarack.

India, one of the world's largest drug producers and exporters, is working to restore confidence after Indian-made cough syrups were linked to the deaths of children in Gambia, Uzbekistan, and Cameroon.

(Reporting by Rishika Sadam; Editing by Leroy Leo)

(([email protected]))

Aug 9 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABS JUNE-QUARTER CONSOL NET PROFIT 5.45 BILLION RUPEES

• ALKEM LABS JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 30.32 BILLION RUPEES

Source text for Eikon: ID:nBSE34w3Gb

Further company coverage: ALKE.NS

(([email protected];))

** Shares of Alkem Laboratories ALKE.NS rise 3.2% to 5,165 rupees; set to snap four-session losing streak

** Drugmaker says US FDA closed inspection at its manufacturing facility in Baddi and classified it as voluntary action indicated (VAI)

** VAI means objectionable conditions or practices were found, but the agency won't recommend any administrative or regulatory action, as per the regulator's website

** ALKE top pct gainer on Nifty pharma index .NIPHARM which is trading flat

** Mean rating of 18 analysts is "hold"; median PT is 4,780 rupees - LSEG data

** Stock down 0.2% this year, erasing most YTD losses, but underperforms NIfty pharma index's 16% climb

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

June 6 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABORATORIES LTD - CO AGREED TO INVEST 300 MILLION RUPEES IN SHARES OF HAYSTACKANALYTICS

• ALKEM LABORATORIES - PROPOSED INVESTMENT WILL HELP CO TO PARTICIPATE IN GROWING DIAGNOSTIC SPACE

Source text for Eikon: ID:nBSEsvr73

Further company coverage: ALKE.NS

(([email protected];))